Women who complain of bladder pain and urinary urgency and frequency wait years to receive the label of interstitial cystitis (IC), an "orphan disease" which has no known cause or cure. The current ...

This study aims to evaluate the long-term outcomes of the novel "three horseshoe-like incision" (3-HSI) technique for holmium laser enucleation of the prostate (HoLEP) compared to the traditional ...

(UroToday.com) The Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank 2025, held in Washington D.C., United States, was host to the session: BCAN 2023 Bladder Cancer Research Innovation ...

Dr. Lerner opened his presentation by discussing the SWOG S1011 trial, a randomized clinical study evaluating the benefit of limited versus extended pelvic lymph node dissection at the time of radical ...

Dr. Jonathan Rosenberg discussed the CALGB 90601 study and titled his talk: From lemons to lemonade, possibilities from negative cooperative group trials. Dr. Rosenberg began by highlighting one of ...

Alan Bryce interviews Tanya Dorff about recommendations from the 2024 US Prostate Cancer Consensus Conference addressing clinical gray areas in prostate cancer management.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Zachary Klaassen hosts Andrew Hahn to discuss future directions in metastatic castration-resistant prostate cancer. Dr. Hahn highlights the "golden era" for targeting cell surface proteins through ...

EVOLUTION study, lutetium PSMA-617, prostate cancer immunotherapy, checkpoint inhibitors, metastatic castration-resistant prostate cancer, EVOLUTION Trial: Ipilimumab/Nivolumab Plus Lutetium-PSMA ...

nadofaragene treatment sequencing, BCG-unresponsive NMIBC therapy, bladder cancer gene therapy, NMIBC treatment options, nadofaragene firadenovec efficacy, Nadofaragene Firadenovec: Efficacy, Dosing, ...

NCI study showing 85% of PSMA-positive BCR patients avoid treatment with surveillance approach, PSMA PET in Biochemical Recurrence: When to Treat vs When to Wait with Ravi Madan, tian zhang.

Evan Yu is joined by Atish Choudhury to discuss a first-in-human trial combining EZH2 and PARP inhibition in metastatic castration-resistant prostate cancer. Dr. Choudhury explains that EZH2 is an ...